ArticleThe American journal on addictions
Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Article in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05039554 (Randomized Trial of Acceptance and Commitment Therapy), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of Acceptance and Commitment Therapy (ACT) and a Care Management App in Primary Care-based Buprenorphine Treatment
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.Addiction science & clinical practice · 2023Trial
- Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes.Journal of substance abuse treatment · 2022Trial
- Older Age Is Associated With Long-Term Retention in Buprenorphine Treatment for Opioid Use Disorder.Journal of the American Geriatrics Society · 2026Article
- MiBUP: A pilot randomized controlled trial of low-dose initiation of buprenorphine for opioid use disorder: Design and rationale.Contemporary clinical trials communications · 2026Article
- Prenatal substance use and mental health comorbidities predict continued use.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- A Randomized Trial Evaluating Acceptance and Commitment Therapy and Smart Phone Care Management Application to Augment Buprenorphine Therapy for Opioid Use and Chronic Pain.Substance use & addiction journal · 2025Article
- Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.BMC primary care · 2024Article
- "Come try it out. Get your foot in the door:" Exploring patient perspectives on low-barrier treatment for opioid use disorder.Drug and alcohol dependence · 2023Article
- Cessation of self-reported opioid use and impacts on co-occurring health conditions.Drug and alcohol dependence · 2023Article
- Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.Addiction science & clinical practice · 2022Article
- Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.Drug and alcohol dependence reports · 2022Article
- Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.Journal of substance abuse treatment · 2020Article
- Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.American journal of public health · 2020Article
- Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.Addiction science & clinical practice · 2019Article
- Opioids and HIV Infection: From Pain Management to Addiction Treatment.Topics in antiviral medicine · 2018Article
- Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.Addiction biology · 2018Article
- Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.Substance abuse · 2018Article
- Psychostimulant drugs for cocaine dependence.The Cochrane database of systematic reviews · 2016Review
- Comparisons of Cocaine-Only, Opioid-Only, and Users of Both Substances in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).Substance use & misuse · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesNational treatment guidelines state that polysubstance users, including cocaine users, may not be appropriate candidates for office-based buprenorphine treatment. However, data to support this recommendation are sparse and conflicting, and the implications of this recommendation may include limiting the usefulness of buprenorphine treatment, as cocaine use is common among opioid-dependent individuals seeking buprenorphine treatment. We compared buprenorphine treatment outcomes (6-month treatment retention and self-reported opioid use over 6 months) in opioid-dependent cocaine users versus non-users who initiated buprenorphine treatment at an urban community health center.
methodsWe followed 87 participants over 6 months, collecting interview and medical record data. We used logistic regression models to test whether baseline cocaine use was associated with treatment retention and mixed effects nonlinear models to test whether baseline cocaine use was associated with self-reported opioid use.
resultsAt baseline, 39.1% reported cocaine use. In all participants, self-reported opioid use decreased from 89.7% to 27.4% over 6 months, and 6-month treatment retention was 54.5%. We found no significant difference in 6-month treatment retention (AOR = 1.56, 95% CI: .58-4.17, p = .38) or self-reported opioid use (AOR = .89, 95% CI: .26-3.07, p = .85) between cocaine users and non-users. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: This study demonstrates that buprenorphine treatment retention is not worse in cocaine users than non-users, with clinically meaningful improvements in self-reported opioid use. These findings suggest that opioid-dependent cocaine users attain considerable benefits from office-based buprenorphine treatment and argue for the inclusion of these patients in office-based buprenorphine treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.